Home/Filings/4/0000950170-24-035447
4//SEC Filing

Shah Sujal 4

Accession 0000950170-24-035447

CIK 0001042074other

Filed

Mar 21, 8:00 PM ET

Accepted

Mar 22, 4:55 PM ET

Size

34.1 KB

Accession

0000950170-24-035447

Insider Transaction Report

Form 4
Period: 2024-03-22
Shah Sujal
Chief Financial Officer
Transactions
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2024-03-22536,0320 total
    Exercise: $4.05Exp: 2030-05-14Common Stock (536,032 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2024-03-22649,9990 total
    Exercise: $2.94Exp: 2032-01-24Common Stock (649,999 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2024-03-22357,5000 total
    Exercise: $22.85Exp: 2034-01-23Common Stock (357,500 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2024-03-22800,0000 total
    Exercise: $7.80Exp: 2033-01-24Common Stock (800,000 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2024-03-22621,1010 total
    Exercise: $9.21Exp: 2027-10-26Common Stock (621,101 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2024-03-22146,8750 total
    Exercise: $11.69Exp: 2028-01-23Common Stock (146,875 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2024-03-22314,1200 total
    Exercise: $8.43Exp: 2029-01-28Common Stock (314,120 underlying)
  • Disposition to Issuer

    Common Stock

    2024-03-2296,2500 total
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2024-03-2239,3750 total
    Exercise: $1.06Exp: 2026-01-25Common Stock (39,375 underlying)
  • Disposition to Issuer

    Common Stock

    2024-03-22310,4200 total
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2024-03-2288,3510 total
    Exercise: $10.00Exp: 2025-01-06Common Stock (88,351 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2024-03-2250,0000 total
    Exercise: $1.82Exp: 2026-07-24Common Stock (50,000 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2024-03-2247,9160 total
    Exercise: $1.72Exp: 2027-01-18Common Stock (47,916 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2024-03-2290,0000 total
    Exercise: $3.48Exp: 2027-04-26Common Stock (90,000 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2024-03-22284,7120 total
    Exercise: $5.78Exp: 2031-01-25Common Stock (284,712 underlying)
Footnotes (3)
  • [F1]Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024 (the "Merger Agreement"), by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding share of CymaBay common stock was converted into the right to receive a cash payment equal to $32.50, less applicable withholding taxes.
  • [F2]Pursuant to the Merger Agreement, each outstanding CymaBay restricted stock unit award was cancelled and converted into the right to receive a cash payment equal to the product of (i) the number of shares of CymaBay common stock subject to such restricted stock unit award and (ii) $32.50, less applicable withholding taxes.
  • [F3]Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.

Documents

1 file

Issuer

CymaBay Therapeutics, Inc.

CIK 0001042074

Entity typeother

Related Parties

1
  • filerCIK 0001588861

Filing Metadata

Form type
4
Filed
Mar 21, 8:00 PM ET
Accepted
Mar 22, 4:55 PM ET
Size
34.1 KB